No Data
No Data
Vanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
H.C. Wainwright Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $18
Cantor Fitzgerald Maintains Vanda Pharmaceuticals(VNDA.US) With Buy Rating, Maintains Target Price $13
Vanda Pharmaceuticals | 10-Q: Q3 2024 Earnings Report
Express News | Vanda Pharmaceuticals Inc : Jefferies Cuts Target Price to $5.5 From $6
Vanda Pharmaceuticals Reports Strong Q3 2024 Growth